EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

LOXL2 in Cancer: A Two-Decade Perspective

Amparo Cano, Pilar Eraso, María J Mazón, Francisco Portillo iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241814405 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Amparo Cano und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Bioquímica UAM, Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas-Universidad Aut…. Hauptthemen laut MEDLINE: Neoplasms, Amine Oxidase (Copper-Containing). Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish Ministry of Science and Innovation MCIN, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lysyl Oxidase Like 2 (LOXL2) belongs to the lysyl oxidase (LOX) family, which comprises five lysine tyrosylquinone (LTQ)-dependent copper amine oxidases in humans. In 2003, LOXL2 was first identified as a promoter of tumour progression and, over the course of two decades, numerous studies have firmly established its involvement in multiple cancers. Extensive research with large cohorts of human tumour samples has demonstrated that dysregulated LOXL2 expression is strongly associated with poor prognosis in patients. Moreover, investigations have revealed the association of LOXL2 with various targets affecting diverse aspects of tumour progression. Additionally, the discovery of a complex network of signalling factors acting at the transcriptional, post-transcriptional, and post-translational levels has provided insights into the mechanisms underlying the aberrant expression of LOXL2 in tumours. Furthermore, the development of genetically modified mouse models with silenced or overexpressed LOXL2 has enabled in-depth exploration of its in vivo role in various cancer models. Given the significant role of LOXL2 in numerous cancers, extensive efforts are underway to identify specific inhibitors that could potentially improve patient prognosis. In this review, we aim to provide a comprehensive overview of two decades of research on the role of LOXL2 in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAmine Oxidase (Copper-Containing)AnimalsMiceHumansProtein-Lysine 6-OxidaseDisease Models, AnimalPromoter Regions, GeneticAmino Acid Oxidoreductases

Stichwörter der Autor:innen

LOXL2human tumour samplemouse modelsregulationtargetstumour progression

Substanzen

Protein-Lysine 6-OxidaseAmine Oxidase (Copper-Containing)LOXL2 protein, humanAmino Acid Oxidoreductases

Autor:innen und Institutionen

  • Departamento de Bioquímica UAM, Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), 28029 Madrid, Spain.
  • Instituto de Investigación Sanitaria del Hospital Universitario La Paz-IdiPAZ, 28029 Madrid, Spain.
  • Centro de Investigación Biomédica en Red, Área de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.

ORCID-Profile: Francisco Portillo

Förderung

  • Spanish Ministry of Science and Innovation MCIN
  • Instituto de Salud Carlos III

Zitieren

APA

Cano, A., Eraso, P., Mazón, M. J., & Portillo, F. (2023). LOXL2 in Cancer: A Two-Decade Perspective. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241814405

Vancouver

Cano A, Eraso P, Mazón MJ, Portillo F. LOXL2 in Cancer: A Two-Decade Perspective. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241814405

BibTeX
@article{Cano2023,
  author = {Cano, Amparo and Eraso, Pilar and Mazón, María J and Portillo, Francisco},
  title = {LOXL2 in Cancer: A Two-Decade Perspective},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241814405}
}
Kostenlos starten →